{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:25:42Z","timestamp":1771320342250,"version":"3.50.1"},"reference-count":73,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Genetic metabolic kidney diseases arise from (likely) pathogenic variants affecting kidney metabolism, causing progressive kidney dysfunction. Symptoms include but are not restricted to nephrolithiasis, proteinuria, kidney failure, and extrarenal manifestations. Genetic testing in combination with metabolic profiling aids early diagnosis and personalized management strategies, which may include enzyme replacement, dietary changes, and kidney-related therapies. Advances in gene therapy and precision medicine offer hope for better outcomes. Early diagnosis and intervention are key to improving prognosis and quality of life, emphasizing the importance of advancing combined metabolic\/genetic testing and treatment approaches.<\/jats:p>","DOI":"10.1515\/medgen-2025-2044","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:58:42Z","timestamp":1771318722000},"page":"39-50","source":"Crossref","is-referenced-by-count":0,"title":["The kidney in genetic metabolic disorders"],"prefix":"10.1515","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7541-5310","authenticated-orcid":false,"given":"Ulla T.","family":"Schultheiss","sequence":"first","affiliation":[{"name":"University of Freiburg Department of Medicine\u00a0IV\u00a0\u2013 Nephrology and Primary Care Hugstetter Str. 49 Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7958-0188","authenticated-orcid":false,"given":"Anke","family":"Schumann","sequence":"additional","affiliation":[{"name":"University of Freiburg Department of Pediatrics, Adolescent Medicine and Neonatology Breisacher Str. 62 Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"2026021708583586259_j_medgen-2025-2044_ref_001","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, \u201cKDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease\u201d, Kidney Int., Bd. 105, Nr. 4S, S. S117\u2013S314, Apr. 2024, doi: 10.1016\/j.kint.2023.10.018.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_002","doi-asserted-by":"crossref","unstructured":"A. Francis u.\u200aa., \u201cChronic kidney disease and the global public health agenda: an international consensus\u201d, Nat. Rev. Nephrol., Bd. 20, Nr. 7, S. 473\u2013485, Juli 2024, doi: 10.1038\/s41581-024-00820-6.","DOI":"10.1038\/s41581-024-00820-6"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_003","doi-asserted-by":"crossref","unstructured":"C. R. Ferreira, S. Rahman, M. Keller, J. Zschocke, und ICIMD Advisory Group, \u201cAn international classification of inherited metabolic disorders (ICIMD)\u201d, J. Inherit. Metab. Dis., Bd. 44, Nr. 1, S. 164\u2013177, Jan. 2021, doi: 10.1002\/jimd.12348.","DOI":"10.1002\/jimd.12348"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_004","doi-asserted-by":"crossref","unstructured":"\u201cKidney disease: a global health priority\u201d, Nat. Rev. Nephrol., Bd. 20, Nr. 7, S. 421\u2013423, Juli 2024, doi: 10.1038\/s41581-024-00829-x.","DOI":"10.1038\/s41581-024-00829-x"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_005","unstructured":"A. Mehta und D. A. Hughes, \u201cFabry Disease\u201d, in GeneReviews\u00ae, M. P. Adam, J. Feldman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, und A. Amemiya, Hrsg., Seattle (WA): University of Washington, Seattle, 1993. Zugegriffen: 29. April 2025. [Online]. Verf\u00fcgbar unter: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1292\/"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_006","unstructured":"S. R. A. Bokhari, H. Zulfiqar, und A. Hariz, \u201cFabry Disease\u201d, in StatPearls, Treasure Island (FL): StatPearls Publishing, 2025. Zugegriffen: 29. April 2025. [Online]. Verf\u00fcgbar unter: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK435996\/"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_007","doi-asserted-by":"crossref","unstructured":"F. M. Platt, A. d\u2019Azzo, B. L. Davidson, E. F. Neufeld, und C. J. Tifft, \u201cLysosomal storage diseases\u201d, Nat. Rev. Dis. Primer, Bd. 4, Nr. 1, S. 27, Okt. 2018, doi: 10.1038\/s41572-018-0025-4.","DOI":"10.1038\/s41572-018-0025-4"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_008","doi-asserted-by":"crossref","unstructured":"P. J. Meikle, J. J. Hopwood, A. E. Clague, und W. F. Carey, \u201cPrevalence of lysosomal storage disorders\u201d, JAMA, Bd. 281, Nr. 3, S. 249\u2013254, Jan. 1999, doi: 10.1001\/jama.281.3.249.","DOI":"10.1001\/jama.281.3.249"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_009","doi-asserted-by":"crossref","unstructured":"A. Tuttolomondo u.\u200aa., \u201cPathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies\u201d, Int. J. Mol. Sci., Bd. 22, Nr. 18, S. 10088, Sep. 2021, doi: 10.3390\/ijms221810088.","DOI":"10.3390\/ijms221810088"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_010","doi-asserted-by":"crossref","unstructured":"B. Coelho-Ribeiro u.\u200aa., \u201cInflammation and Exosomes in Fabry Disease Pathogenesis\u201d, Cells, Bd. 13, Nr. 8, S. 654, Apr. 2024, doi: 10.3390\/cells13080654.","DOI":"10.3390\/cells13080654"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_011","doi-asserted-by":"crossref","unstructured":"P. Li u.\u200aa., \u201cGLA Mutations Suppress Autophagy and Stimulate Lysosome Generation in Fabry Disease\u201d, Cells, Bd. 13, Nr. 5, S. 437, M\u00e4rz 2024, doi: 10.3390\/cells13050437.","DOI":"10.3390\/cells13050437"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_012","doi-asserted-by":"crossref","unstructured":"L. Choi u.\u200aa., \u201cThe Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain\u201d, Neurosci. Lett., Bd. 594, S. 163\u2013168, Mai 2015, doi: 10.1016\/j.neulet.2015.01.084.","DOI":"10.1016\/j.neulet.2015.01.084"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_013","doi-asserted-by":"crossref","unstructured":"M. Del Pino u.\u200aa., \u201cFabry Nephropathy: An Evidence-Based Narrative Review\u201d, Kidney Blood Press. Res., Bd. 43, Nr. 2, S. 406\u2013421, 2018, doi: 10.1159\/000488121.","DOI":"10.1159\/000488121"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_014","doi-asserted-by":"crossref","unstructured":"S.-Y. Kim u.\u200aa., \u201cRIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death\u201d, Cells, Bd. 10, Nr. 2, S. 245, Jan. 2021, doi: 10.3390\/cells10020245.","DOI":"10.3390\/cells10020245"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_015","doi-asserted-by":"crossref","unstructured":"Y. Yuan u.\u200aa., \u201cInflammatory cytokine expression in Fabry disease: impact of disease phenotype and alterations under enzyme replacement therapy\u201d, Front. Immunol., Bd. 15, S. 1367252, 2024, doi: 10.3389\/fimmu.2024.1367252.","DOI":"10.3389\/fimmu.2024.1367252"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_016","doi-asserted-by":"crossref","unstructured":"V. Nikolaenko, D. G. Warnock, K. Mills, und W. E. Heywood, \u201cElucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease\u201d, Hum. Mol. Genet., Bd. 32, Nr. 15, S. 2464\u20132472, Juli 2023, doi: 10.1093\/hmg\/ddad073.","DOI":"10.1093\/hmg\/ddad073"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_017","doi-asserted-by":"crossref","unstructured":"M. D. Elliott, H. M. Rasouly, und A. G. Gharavi, \u201cGenetics of Kidney Disease: The Unexpected Role of Rare Disorders\u201d, Annu. Rev. Med., Bd. 74, S. 353\u2013367, Jan. 2023, doi: 10.1146\/annurev-med-042921-101813.","DOI":"10.1146\/annurev-med-042921-101813"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_018","doi-asserted-by":"crossref","unstructured":"M. Beck u.\u200aa., \u201cTwenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry\u201d, Orphanet J. Rare Dis., Bd. 17, Nr. 1, S. 238, Juni 2022, doi: 10.1186\/s13023-022-02392-9.","DOI":"10.1186\/s13023-022-02392-9"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_019","doi-asserted-by":"crossref","unstructured":"E. Okada u.\u200aa., \u201cAll reported non-canonical splice site variants in GLA cause aberrant splicing\u201d, Clin. Exp. Nephrol., Bd. 27, Nr. 9, S. 737\u2013746, Sep. 2023, doi: 10.1007\/s10157-023-02361-x.","DOI":"10.1007\/s10157-023-02361-x"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_020","doi-asserted-by":"crossref","unstructured":"R. Blanco u.\u200aa., \u201cPhenotypic Expression and Outcomes in Patients with the p.Arg301Gln GLA Variant in Anderson-Fabry Disease\u201d, Int. J. Mol. Sci., Bd. 25, Nr. 8, S. 4299, Apr. 2024, doi: 10.3390\/ijms25084299.","DOI":"10.21203\/rs.3.rs-3668933\/v1"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_021","doi-asserted-by":"crossref","unstructured":"R. Izhar u.\u200aa., \u201cFabry Disease in Women: Genetic Basis, Available Biomarkers, and Clinical Manifestations\u201d, Genes, Bd. 15, Nr. 1, S. 37, Dez. 2023, doi: 10.3390\/genes15010037.","DOI":"10.3390\/genes15010037"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_022","doi-asserted-by":"crossref","unstructured":"D. A. Hughes u.\u200aa., \u201cOral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study\u201d, J. Med. Genet., Bd. 54, Nr. 4, S. 288\u2013296, Apr. 2017, doi: 10.1136\/jmedgenet-2016-104178.","DOI":"10.1136\/jmedgenet-2016-104178"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_023","doi-asserted-by":"crossref","unstructured":"V. Khare und S. Cherqui, \u201cTargeted gene therapy for rare genetic kidney diseases\u201d, Kidney Int., Bd. 106, Nr. 6, S. 1051\u20131061, Dez. 2024, doi: 10.1016\/j.kint.2024.07.034.","DOI":"10.1016\/j.kint.2024.07.034"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_024","doi-asserted-by":"crossref","unstructured":"J. Rodr\u00edguez-Castej\u00f3n u.\u200aa., \u201c\u03b1-Galactosidase A Augmentation by Non-Viral Gene Therapy: Evaluation in Fabry Disease Mice\u201d, Pharmaceutics, Bd. 13, Nr. 6, S. 771, Mai 2021, doi: 10.3390\/pharmaceutics13060771.","DOI":"10.3390\/pharmaceutics13060771"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_025","doi-asserted-by":"crossref","unstructured":"J. D. Rubin, T. V. Nguyen, K. L. Allen, K. Ayasoufi, und M. A. Barry, \u201cComparison of Gene Delivery to the Kidney by Adenovirus, Adeno-Associated Virus, and Lentiviral Vectors After Intravenous and Direct Kidney Injections\u201d, Hum. Gene Ther., Bd. 30, Nr. 12, S. 1559\u20131571, Dez. 2019, doi: 10.1089\/hum.2019.127.","DOI":"10.1089\/hum.2019.127"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_026","doi-asserted-by":"crossref","unstructured":"C. J. Rocca, S. N. Ur, F. Harrison, und S. Cherqui, \u201crAAV9 combined with renal vein injection is optimal for kidney-targeted gene delivery: conclusion of a comparative study\u201d, Gene Ther., Bd. 21, Nr. 6, S. 618\u2013628, Juni 2014, doi: 10.1038\/gt.2014.35.","DOI":"10.1038\/gt.2014.35"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_027","doi-asserted-by":"crossref","unstructured":"A. Khan u.\u200aa., \u201cLentivirus-mediated gene therapy for Fabry disease\u201d, Nat. Commun., Bd. 12, Nr. 1, S. 1178, Feb. 2021, doi: 10.1038\/s41467-021-21371-5.","DOI":"10.1038\/s41467-021-21371-5"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_028","doi-asserted-by":"crossref","unstructured":"A. Schumann u.\u200aa., \u201cKidney involvement in glycogen storage disease type I: Current knowledge and key challenges\u201d, Mol. Genet. Metab., Bd. 144, Nr. 3, S. 109054, M\u00e4rz 2025, doi: 10.1016\/j.ymgme.2025.109054.","DOI":"10.1016\/j.ymgme.2025.109054"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_029","doi-asserted-by":"crossref","unstructured":"J. Y. Chou, D. Matern, B. C. Mansfield, und Y.-T. Chen, \u201cType I glycogen storage diseases: disorders of the glucose-6-phosphatase complex\u201d, Curr. Mol. Med., Bd. 2, Nr. 2, S. 121\u2013143, M\u00e4rz 2002, doi: 10.2174\/1566524024605798.","DOI":"10.2174\/1566524024605798"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_030","unstructured":"D. S. Bali, A. El-Gharbawy, S. Austin, S. Pendyal, und P. S. Kishnani, \u201cGlycogen Storage Disease Type I\u201d, in GeneReviews\u00ae, M. P. Adam, J. Feldman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, und A. Amemiya, Hrsg., Seattle (WA): University of Washington, Seattle, 1993. Zugegriffen: 25. Juni 2025. [Online]. Verf\u00fcgbar unter: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1312\/"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_031","doi-asserted-by":"crossref","unstructured":"P. S. Kishnani u.\u200aa., \u201cDiagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics\u201d, Genet. Med. Off. J. Am. Coll. Med. Genet., Bd. 16, Nr. 11, S. e1, Nov. 2014, doi: 10.1038\/gim.2014.128.","DOI":"10.1038\/gim.2014.128"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_032","doi-asserted-by":"crossref","unstructured":"D. A. Weinstein, M. J. Somers, und J. I. Wolfsdorf, \u201cDecreased urinary citrate excretion in type 1a glycogen storage disease\u201d, J. Pediatr., Bd. 138, Nr. 3, S. 378\u2013382, M\u00e4rz 2001, doi: 10.1067\/mpd.2001.111322.","DOI":"10.1067\/mpd.2001.111322"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_033","doi-asserted-by":"crossref","unstructured":"D. H. J. Martens, J. P. Rake, G. Navis, V. Fidler, C. M. L. van Dael, und G. P. A. Smit, \u201cRenal function in glycogen storage disease type I, natural course, and renopreservative effects of ACE inhibition\u201d, Clin. J. Am. Soc. Nephrol. CJASN, Bd. 4, Nr. 11, S. 1741\u20131746, Nov. 2009, doi: 10.2215\/CJN.00050109.","DOI":"10.2215\/CJN.00050109"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_034","doi-asserted-by":"crossref","unstructured":"W. H. Yiu u.\u200aa., \u201cAngiotensin mediates renal fibrosis in the nephropathy of glycogen storage disease type Ia\u201d, Kidney Int., Bd. 73, Nr. 6, S. 716\u2013723, M\u00e4rz 2008, doi: 10.1038\/sj.ki.5002718.","DOI":"10.1038\/sj.ki.5002718"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_035","doi-asserted-by":"crossref","unstructured":"Y.-T. Chen, R. A. Coleman, J. I. Scheinman, P. C. Kolbeck, und J. B. Sidbury, \u201cRenal Disease in Type I Glycogen Storage Disease\u201d, N. Engl. J. Med., Bd. 318, Nr. 1, S. 7\u201311, Jan. 1988, doi: 10.1056\/NEJM198801073180102.","DOI":"10.1056\/NEJM198801073180102"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_036","doi-asserted-by":"crossref","unstructured":"M. Dambska, E. B. Labrador, C. L. Kuo, und D. A. Weinstein, \u201cPrevention of complications in glycogen storage disease type Ia with optimization of metabolic control\u201d, Pediatr. Diabetes, Bd. 18, Nr. 5, S. 327\u2013331, Aug. 2017, doi: 10.1111\/pedi.12540.","DOI":"10.1111\/pedi.12540"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_037","doi-asserted-by":"crossref","unstructured":"D. Melis u.\u200aa., \u201cEfficacy of ACE-inhibitor therapy on renal disease in glycogen storage disease type 1: a multicentre retrospective study\u201d, Clin. Endocrinol. (Oxf.), Bd. 63, Nr. 1, S. 19\u201325, Juli 2005, doi: 10.1111\/j.1365-2265.2005.02292.x.","DOI":"10.1111\/j.1365-2265.2005.02292.x"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_038","doi-asserted-by":"crossref","unstructured":"J. I. Wolfsdorf, L. M. Laffel, und J. F. Crigler, \u201cMetabolic control and renal dysfunction in type I glycogen storage disease\u201d, J. Inherit. Metab. Dis., Bd. 20, Nr. 4, S. 559\u2013568, Aug. 1997, doi: 10.1023\/a:1005346824368.","DOI":"10.1023\/A:1005346824368"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_039","doi-asserted-by":"crossref","unstructured":"F. Rajas, P. Labrune, und G. Mithieux, \u201cGlycogen storage disease type 1 and diabetes: learning by comparing and contrasting the two disorders\u201d, Diabetes Metab., Bd. 39, Nr. 5, S. 377\u2013387, Okt. 2013, doi: 10.1016\/j.diabet.2013.03.002.","DOI":"10.1016\/j.diabet.2013.03.002"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_040","doi-asserted-by":"crossref","unstructured":"M. D\u2019Acierno u.\u200aa., \u201cDapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b\u201d, J. Am. Soc. Nephrol. JASN, Bd. 33, Nr. 10, S. 1864\u20131875, Okt. 2022, doi: 10.1681\/ASN.2021070935.","DOI":"10.1681\/ASN.2021070935"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_041","doi-asserted-by":"crossref","unstructured":"J. Baruteau, N. Brunetti-Pierri, und P. Gissen, \u201cLiver-directed gene therapy for inherited metabolic diseases\u201d, J. Inherit. Metab. Dis., Bd. 47, Nr. 1, S. 9\u201321, Jan. 2024, doi: 10.1002\/jimd.12709.","DOI":"10.1002\/jimd.12709"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_042","doi-asserted-by":"crossref","unstructured":"L. Mansour-Hendili u.\u200aa., \u201cMutation Update of the CLCN5 Gene Responsible for Dent Disease 1\u201d, Hum. Mutat., Bd. 36, Nr. 8, S. 743\u2013752, Aug. 2015, doi: 10.1002\/humu.22804.","DOI":"10.1002\/humu.22804"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_043","doi-asserted-by":"crossref","unstructured":"R. R. Hoopes u.\u200aa., \u201cDent Disease with Mutations in OCRL1\u201d, Am. J. Hum. Genet., Bd. 76, Nr. 2, S. 260\u2013267, Feb. 2005, doi: 10.1086\/427887.","DOI":"10.1086\/427887"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_044","doi-asserted-by":"crossref","unstructured":"A. B\u00f6kenkamp u.\u200aa., \u201cDent disease: clinical practice recommendations\u201d, Nephrol. Dial. Transplant., Bd. 40, Nr. 5, S. 852\u2013864, Apr. 2025, doi: 10.1093\/ndt\/gfaf003.","DOI":"10.1093\/ndt\/gfaf003"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_045","doi-asserted-by":"crossref","unstructured":"O. Devuyst, \u201cIntra-renal and subcellular distribution of the human chloride channel, CLC-5, reveals a pathophysiological basis for Dent\u2019s disease\u201d, Hum. Mol. Genet., Bd. 8, Nr. 2, S. 247\u2013257, Feb. 1999, doi: 10.1093\/hmg\/8.2.247.","DOI":"10.1093\/hmg\/8.2.247"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_046","doi-asserted-by":"crossref","unstructured":"B.-C. Liu, T.-T. Tang, L.-L. Lv, und H.-Y. Lan, \u201cRenal tubule injury: a driving force toward chronic kidney disease\u201d, Kidney Int., Bd. 93, Nr. 3, S. 568\u2013579, M\u00e4rz 2018, doi: 10.1016\/j.kint.2017.09.033.","DOI":"10.1016\/j.kint.2017.09.033"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_047","doi-asserted-by":"crossref","unstructured":"G. Priante u.\u200aa., \u201cEmerging Perspectives on the Rare Tubulopathy Dent Disease: Is Glomerular Damage a Direct Consequence of ClC-5 Dysfunction?\u201d, Int. J. Mol. Sci., Bd. 24, Nr. 2, S. 1313, Jan. 2023, doi: 10.3390\/ijms24021313.","DOI":"10.3390\/ijms24021313"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_048","doi-asserted-by":"crossref","unstructured":"L. Gianesello, D. Del Prete, F. Anglani, und L. A. Cal\u00f2, \u201cGenetics and phenotypic heterogeneity of Dent disease: the dark side of the moon\u201d, Hum. Genet., Bd. 140, Nr. 3, S. 401\u2013421, M\u00e4rz 2021, doi: 10.1007\/s00439-020-02219-2.","DOI":"10.1007\/s00439-020-02219-2"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_049","doi-asserted-by":"crossref","unstructured":"M. G. Arnous u.\u200aa., \u201cThe Site and Type of CLCN5 Genetic Variation Impact the Resulting Dent Disease-1 Phenotype\u201d, Kidney Int. Rep., Bd. 8, Nr. 6, S. 1220\u20131230, Juni 2023, doi: 10.1016\/j.ekir.2023.03.012.","DOI":"10.1016\/j.ekir.2023.03.012"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_050","doi-asserted-by":"crossref","unstructured":"L. Gianesello u.\u200aa., \u201cGenotype Phenotype Correlation in Dent Disease 2 and Review of the Literature: OCRL Gene Pleiotropism or Extreme Phenotypic Variability of Lowe Syndrome?\u201d, Genes, Bd. 12, Nr. 10, S. 1597, Okt. 2021, doi: 10.3390\/genes12101597.","DOI":"10.3390\/genes12101597"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_051","doi-asserted-by":"crossref","unstructured":"P. Forny u.\u200aa., \u201cGuidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision\u201d, J. Inherit. Metab. Dis., Bd. 44, Nr. 3, S. 566\u2013592, Mai 2021, doi: 10.1002\/jimd.12370.","DOI":"10.1002\/jimd.12370"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_052","doi-asserted-by":"crossref","unstructured":"N. Boy u.\u200aa., \u201cRecommendations for diagnosing and managing individuals with glutaric aciduria type 1: Third revision\u201d, J. Inherit. Metab. Dis., Bd. 46, Nr. 3, S. 482\u2013519, Mai 2023, doi: 10.1002\/jimd.12566.","DOI":"10.1002\/jimd.12566"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_053","unstructured":"I. Manoli, J. L. Sloan, und C. P. Venditti, \u201cIsolated Methylmalonic Acidemia\u201d, in GeneReviews\u00ae, M. P. Adam, J. Feldman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, und A. Amemiya, Hrsg., Seattle (WA): University of Washington, Seattle, 1993. Zugegriffen: 25. Juni 2025. [Online]. Verf\u00fcgbar unter: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1231\/"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_054","doi-asserted-by":"crossref","unstructured":"F. H\u00f6rster u.\u200aa., \u201cDelineating the clinical spectrum of isolated methylmalonic acidurias: cblA and mut\u201d, J. Inherit. Metab. Dis., Bd. 44, Nr. 1, S. 193\u2013214, Jan. 2021, doi: 10.1002\/jimd.12297.","DOI":"10.1002\/jimd.12297"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_055","doi-asserted-by":"crossref","unstructured":"L. Dello Strologo u.\u200aa., \u201cRenal outcome and plasma methylmalonic acid levels after isolated or combined liver or kidney transplantation in patients with methylmalonic acidemia: A multicenter analysis\u201d, Mol. Genet. Metab., Bd. 137, Nr. 3, S. 265\u2013272, Nov. 2022, doi: 10.1016\/j.ymgme.2022.09.010.","DOI":"10.1016\/j.ymgme.2022.09.010"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_056","doi-asserted-by":"crossref","unstructured":"M. Dao u.\u200aa., \u201cLong-term renal outcome in methylmalonic acidemia in adolescents and adults\u201d, Orphanet J. Rare Dis., Bd. 16, Nr. 1, S. 220, Mai 2021, doi: 10.1186\/s13023-021-01851-z.","DOI":"10.1186\/s13023-021-01851-z"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_057","doi-asserted-by":"crossref","unstructured":"M. A. Cosson u.\u200aa., \u201cLong-term outcome in methylmalonic aciduria: a series of 30 French patients\u201d, Mol. Genet. Metab., Bd. 97, Nr. 3, S. 172\u2013178, Juli 2009, doi: 10.1016\/j.ymgme.2009.03.006.","DOI":"10.1016\/j.ymgme.2009.03.006"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_058","doi-asserted-by":"crossref","unstructured":"I. Manoli u.\u200aa., \u201cTargeting proximal tubule mitochondrial dysfunction attenuates the renal disease of methylmalonic acidemia\u201d, Proc. Natl. Acad. Sci. U. S. A., Bd. 110, Nr. 33, S. 13552\u201313557, Aug. 2013, doi: 10.1073\/pnas.1302764110.","DOI":"10.1073\/pnas.1302764110"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_059","doi-asserted-by":"crossref","unstructured":"Z. K. Zsengell\u00e9r u.\u200aa., \u201cMethylmalonic acidemia: a megamitochondrial disorder affecting the kidney\u201d, Pediatr. Nephrol. Berl. Ger., Bd. 29, Nr. 11, S. 2139\u20132146, Nov. 2014, doi: 10.1007\/s00467-014-2847-y.","DOI":"10.1007\/s00467-014-2847-y"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_060","doi-asserted-by":"crossref","unstructured":"A. Luciani u.\u200aa., \u201cImpaired mitophagy links mitochondrial disease to epithelial stress in methylmalonyl-CoA mutase deficiency\u201d, Nat. Commun., Bd. 11, Nr. 1, S. 970, Feb. 2020, doi: 10.1038\/s41467-020-14729-8.","DOI":"10.1038\/s41467-020-14729-8"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_061","doi-asserted-by":"crossref","unstructured":"A. Schumann u.\u200aa., \u201cThe impact of metabolic stressors on mitochondrial homeostasis in a renal epithelial cell model of methylmalonic aciduria\u201d, Sci. Rep., Bd. 13, Nr. 1, S. 7677, Mai 2023, doi: 10.1038\/s41598-023-34373-8.","DOI":"10.1038\/s41598-023-34373-8"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_062","doi-asserted-by":"crossref","unstructured":"M. Ugarte u.\u200aa., \u201cOverview of mutations in the PCCA and PCCB genes causing propionic acidemia\u201d, Hum. Mutat., Bd. 14, Nr. 4, S. 275\u2013282, 1999, doi: 10.1002\/(SICI)1098-1004(199910)14:4<275::AID-HUMU1>3.0.CO;2-N.","DOI":"10.1002\/(SICI)1098-1004(199910)14:4<275::AID-HUMU1>3.0.CO;2-N"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_063","doi-asserted-by":"crossref","unstructured":"A. AlGhamdi u.\u200aa., \u201cEpilepsy in Propionic Acidemia: Case Series of 14 Saudi Patients\u201d, J. Child Neurol., Bd. 33, Nr. 11, S. 713\u2013717, Okt. 2018, doi: 10.1177\/0883073818786157.","DOI":"10.1177\/0883073818786157"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_064","doi-asserted-by":"crossref","unstructured":"S. K\u00f6lker u.\u200aa., \u201cThe phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype\u201d, J. Inherit. Metab. Dis., Bd. 38, Nr. 6, S. 1059\u20131074, Nov. 2015, doi: 10.1007\/s10545-015-9840-x.","DOI":"10.1007\/s10545-015-9840-x"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_065","doi-asserted-by":"crossref","unstructured":"O. A. Shchelochkov u.\u200aa., \u201cChronic kidney disease in propionic acidemia\u201d, Genet. Med. Off. J. Am. Coll. Med. Genet., Bd. 21, Nr. 12, S. 2830\u20132835, Dez. 2019, doi: 10.1038\/s41436-019-0593-z.","DOI":"10.1038\/s41436-019-0593-z"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_066","doi-asserted-by":"crossref","unstructured":"C. Lam, L. R. Desviat, C. Perez-Cerd\u00e1, M. Ugarte, B. A. Barshop, und S. Cederbaum, \u201c45-Year-old female with propionic acidemia, renal failure, and premature ovarian failure; late complications of propionic acidemia?\u201d, Mol. Genet. Metab., Bd. 103, Nr. 4, S. 338\u2013340, Aug. 2011, doi: 10.1016\/j.ymgme.2011.04.007.","DOI":"10.1016\/j.ymgme.2011.04.007"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_067","doi-asserted-by":"crossref","unstructured":"H. J. Vernon, S. Bagnasco, A. Hamosh, und C. J. Sperati, \u201cChronic kidney disease in an adult with propionic acidemia\u201d, JIMD Rep., Bd. 12, S. 5\u201310, 2014, doi: 10.1007\/8904_2013_237.","DOI":"10.1007\/8904_2013_237"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_068","doi-asserted-by":"crossref","unstructured":"B. Pode-Shakked u.\u200aa., \u201cGlutaric Aciduria type I and acute renal failure \u2013 Coincidence or causality?\u201d, Mol. Genet. Metab. Rep., Bd. 1, S. 170\u2013175, 2014, doi: 10.1016\/j.ymgmr.2014.03.001.","DOI":"10.1016\/j.ymgmr.2014.03.001"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_069","doi-asserted-by":"crossref","unstructured":"M. du Moulin u.\u200aa., \u201cGlutaric Aciduria Type 1 and Acute Renal Failure: Case Report and Suggested Pathomechanisms\u201d, JIMD Rep., Bd. 39, S. 25\u201330, 2018, doi: 10.1007\/8904_2017_44.","DOI":"10.1007\/8904_2017_44"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_070","doi-asserted-by":"crossref","unstructured":"A. P. P\u00f6ge, F. Autschbach, H. Korall, F. K. Trefz, und E. Mayatepek, \u201cEarly clinical manifestation of glutaric aciduria type I and nephrotic syndrome during the first months of life\u201d, Acta Paediatr. Oslo Nor. 1992, Bd. 86, Nr. 10, S. 1144\u20131147, Okt. 1997, doi: 10.1111\/j.1651-2227.1997.tb14827.x.","DOI":"10.1111\/j.1651-2227.1997.tb14827.x"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_071","doi-asserted-by":"crossref","unstructured":"S. K\u00f6lker u.\u200aa., \u201cErratum to: The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype\u201d, J. Inherit. Metab. Dis., Bd. 38, Nr. 6, S. 1157\u20131158, Nov. 2015, doi: 10.1007\/s10545-015-9868-y.","DOI":"10.1007\/s10545-015-9868-y"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_072","doi-asserted-by":"crossref","unstructured":"B. Thies u.\u200aa., \u201cAcute renal proximal tubule alterations during induced metabolic crises in a mouse model of glutaric aciduria type 1\u201d, Biochim. Biophys. Acta, Bd. 1832, Nr. 10, S. 1463\u20131472, Okt. 2013, doi: 10.1016\/j.bbadis.2013.04.019.","DOI":"10.1016\/j.bbadis.2013.04.019"},{"key":"2026021708583586259_j_medgen-2025-2044_ref_073","doi-asserted-by":"crossref","unstructured":"M. Gonzalez Melo u.\u200aa., \u201cA knock-in rat model unravels acute and chronic renal toxicity in glutaric aciduria type I\u201d, Mol. Genet. Metab., Bd. 134, Nr. 4, S. 287\u2013300, Dez. 2021, doi: 10.1016\/j.ymgme.2021.10.003.","DOI":"10.1016\/j.ymgme.2021.10.003"}],"container-title":["Medizinische Genetik"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2025-2044\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2025-2044\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:59:23Z","timestamp":1771318763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/medgen-2025-2044\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,18]]},"published-print":{"date-parts":[[2026,2,3]]}},"alternative-id":["10.1515\/medgen-2025-2044"],"URL":"https:\/\/doi.org\/10.1515\/medgen-2025-2044","relation":{},"ISSN":["1863-5490","0936-5931"],"issn-type":[{"value":"1863-5490","type":"electronic"},{"value":"0936-5931","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}